Terumo (OTCMKTS:TRUMY) Shares Down 7.4% on Disappointing Earnings

Terumo Corp. (OTCMKTS:TRUMY)’s stock price was down 7.4% during trading on Thursday following a weaker than expected earnings announcement. The company traded as low as $14.54 and last traded at $14.6184. Approximately 5,467 shares changed hands during trading, a decline of 98% from the average daily volume of 233,699 shares. The stock had previously closed at $15.78.

The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.06). Terumo had a net margin of 13.83% and a return on equity of 10.44%.

Analysts Set New Price Targets

A number of research firms recently issued reports on TRUMY. Nomura raised shares of Terumo from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 30th. Zacks Research raised Terumo from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 13th. Two research analysts have rated the stock with a Strong Buy rating. According to MarketBeat.com, Terumo presently has a consensus rating of “Strong Buy”.

Terumo Stock Performance

The firm has a 50 day simple moving average of $14.83 and a 200-day simple moving average of $14.08. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.19 and a quick ratio of 1.37. The company has a market cap of $21.56 billion, a price-to-earnings ratio of 20.59 and a beta of 0.82.

About Terumo

Terumo Corporation is a Japan-based medical technology company that develops and manufactures products for hospitals, clinics and other healthcare providers. Founded in 1921, the company began by producing clinical thermometers and has since expanded into a broad range of medical devices and services. Terumo’s businesses include cardiovascular and vascular products, such as catheter-based devices and systems used in the treatment of heart and vascular conditions; medical care products, including infusion and injection devices; and blood and cell technologies used to collect, process and manage blood and cellular therapies.